In Regard to Chen et al

To the Editor: Currently, immune checkpoint inhibitors (ICI) are one of the most appealing topics, and it is important and essential to work on concurrent usage of ICIs and radiation therapy. In the March 2018 issue of the International Journal of Radiation Oncology, Biology, Physics, Chen et al published a truly appealing, and one of the largest, retrospective series in the literature (1). We read the article with great interest, yet 3 main issues are identified in the article that need further clarification for the understanding of the paper.

https://ift.tt/2JPvcBL